Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...

7×24小时香港交易所－R（80388）股票快讯，包括最近香港交易所－R（80388）股票市场行情资讯和影响股票涨跌的国际与经济时事。今日香港交易所－R股票最新消息与行情走势尽在掌握。 快手-W(01024)10月30日斥资1197.42万港元回购25.9万股 智通财经APP讯，快手-W(01024)发布公告，于2024年10月30日斥资1197.42万港元回购股份25.9万股，每股回购... 提 ...

长期使用糖皮质激素会对骨骼健康产生显著影响，其中糖皮质激素诱导的骨质疏松症（GIOP）是最为常见的后果。此前研究表明，苍术内酯 I（Atractylenolide I，Atr I）具有抗炎、抗氧化和抗肿瘤特性，然而其对破骨细胞生成以及 GIOP 的具体作用仍不明确。在本研究中，体外实验结果显示，Atr I 以剂量依赖的方式抑制核因子 κB 受体活化因子配体（RANKL）刺激的破骨细胞分化，破坏成熟 ...

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...

近年来，AKK及其巴氏杀菌形式pasteurized AKK（pAKK）因在缓解代谢疾病、炎症的潜在作用而备受关注。但是，AKK的作用并非全然有益。已有研究发现，AKK与某些自身免疫性疾病和神经系统疾病存在关联。

US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat ...

STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...

全人源抗PD-1单克隆抗体在实体瘤中的安全性和有效性研究。 新型RANKL抑制剂（IgG4亚型）治疗骨转移患者的疗效与安全性研究。 课题资助分类 该项目共支持约18项科研课题： 面上课题：支持4-6项，每项约12-15万元人民币，适用于单中心或中等规模多中心临床研究 ...

Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue). By binding to and inhibiting RANKL, denosumab ...

OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA) for all indications referencing Prolia and Xgeva, respectively Samsung Bioepis’ first endocrinology biosimilar to be ...